Engagement with partners
The University of Newcastle works collaboratively with industry, business and government to research and develop innovative solutions to real-world problems.
Engagement with partners and productive collaborations are essential if world-class research is to translate into outcomes that will change the lives of individuals, the productivity of industry, or the economic health and sustainability of nations.
Our two research institutes Newcastle Institute for Energy and Resources (NIER) and the Hunter Medical Research Institute (HMRI) are examples of our successful industry partnerships.
With our partners UoN researchers have made remarkable contributions to the knowledge and understanding of issues of global significance across many discipline areas. Below are just a few case study examples of our contributions to world-class innovations.
Innovation Case Studies
The 'Jameson Cell' at the UoN - Developed in the 1980's, the revolutionary method of separating valuable minerals and coal from low-yield sources, is now used in 25 countries around the world. Hailed as one of the country's most financially successful inventions in the past two decades, the Jameson Cell adds more than $1.5 billion a year to the value of Australia's minerals export industry.
Image: A Jameson Call at Red Dog zinc-lead mine in Alaska, above the Arctic Circle.
The Centre for Optimal Planning and Operations (C-OPT)uses quantitative methods to help businesses improve their processes and decision making, resulting in increased efficiency and productivity.
C-OPT has created decision support tools for businesses such as Aurizon, one of Australia's largest rail and road-based freight transport providers, the Hunter Valley Coal Chain Coordinator, responsible for managing the world's largest and most complex coal export operation, and Macquarie Generation, one of Australia's largest electricity generators.
The Australian and New Zealand Breast Cancer Trials Group (ANZBCTG), conducts national and international clinical trials to develop new treatments for all types of breast cancer and ultimately for the prevention of breast cancer.
A comparative study by ANZBCTG of treatments for hormone receptor positive breast cancer in post-menopausal women led to the adoption of an alternative to the standard in use at the time of the study for the early treatment of this type of breast cancer. It is estimated that in excess of one million women world-wide have been impacted by the findings of this research.
Image: Professor John Forbes led the study of treatments for hormone receptor positive breast cancer in post-menopausal women.